Gut microbiome-brain-cirrhosis axis DOI Open Access
Maren L. Smith, James B. Wade, Jennifer T. Wolstenholme

и другие.

Hepatology, Год журнала: 2023, Номер 80(2), С. 465 - 485

Опубликована: Март 3, 2023

Cirrhosis is characterized by inflammation, degeneration, and fibrosis of liver tissue. Along with being the most common cause failure transplant, cirrhosis a significant risk factor for several neuropsychiatric conditions. The these HE, which cognitive ataxic symptoms, resulting from buildup metabolic toxins failure. However, patients also show significantly increased neurodegenerative diseases such as Alzheimer Parkinson diseases, mood disorders anxiety depression. In recent years, more attention has been played to communication between ways gut communicate each other central nervous system, way organs influence other’s function. This bidirectional come be known gut-liver-brain axis. microbiome emerged key mechanism affecting gut-liver, gut-brain, brain-liver communication. Clinical studies animal models have demonstrated patterns dysbiosis when present, both or without concomitant alcohol use disorder, provided compelling evidence that this influences mood-related behaviors. review, we summarized pathophysiological effects associated cirrhosis, links cirrhosis-associated disruption microbiome, current clinical preclinical modulation treatment

Язык: Английский

The gut–liver axis and gut microbiota in health and liver disease DOI
Cynthia L. Hsu, Bernd Schnabl

Nature Reviews Microbiology, Год журнала: 2023, Номер 21(11), С. 719 - 733

Опубликована: Июнь 14, 2023

Язык: Английский

Процитировано

234

The microbiota in cirrhosis and its role in hepatic decompensation DOI Creative Commons
Jonel Trebicka, Jane Macnaughtan, Bernd Schnabl

и другие.

Journal of Hepatology, Год журнала: 2021, Номер 75, С. S67 - S81

Опубликована: Май 23, 2021

Cirrhosis - the common end-stage of chronic liver disease is associated with a cascade events, which intestinal bacterial overgrowth and dysbiosis are central. Bacterial toxins entering portal or systemic circulation can directly cause hepatocyte death, while also affects gut barrier function increases translocation, leading to infections, inflammation vasodilation, contribute acute decompensation organ failure. Acute its severe forms, pre-acute-on-chronic failure (ACLF) ACLF, characterised by sudden dysfunction (and failure) high short-term mortality. Patients pre-ACLF ACLF present high-grade inflammation, usually precipitated proven infection and/or alcoholic hepatitis. However, no precipitant identified in 30% these patients, whom translocation from microbiota assumed be responsible for decompensation. Different profiles may influence rate thereby outcome patients. Thus, targeting promising strategy prevention treatment decompensation, ACLF. Approaches include use antibiotics such as rifaximin, faecal microbial transplantation enterosorbents (e.g. Yaq-001), bind factors without exerting direct effect on growth kinetics. This review focuses role strategies prevent

Язык: Английский

Процитировано

176

Immunological mechanisms and therapeutic targets of fatty liver diseases DOI Creative Commons
Hua Wang, Wajahat Z. Mehal, Laura E. Nagy

и другие.

Cellular and Molecular Immunology, Год журнала: 2020, Номер 18(1), С. 73 - 91

Опубликована: Дек. 2, 2020

Abstract Alcoholic liver disease (ALD) and nonalcoholic fatty (NAFLD) are the two major types of chronic worldwide. Inflammatory processes play key roles in pathogeneses diseases, continuous inflammation promotes progression alcoholic steatohepatitis (ASH) (NASH). Although both ALD NAFLD closely related to inflammation, their respective developmental mechanisms differ some extent. Here, we review multiple immunological therapeutic targets associated with diseases differences ASH NASH. Multiple cell liver, including macrophages, neutrophils, other immune hepatocytes, involved inflammation. In addition, microRNAs (miRNAs), extracellular vesicles (EVs), complement also contribute inflammatory process, as does intertissue crosstalk between intestine, adipose tissue, nervous system. We point out that plays important promoting repair controlling bacterial infections. Understanding complex regulatory process disrupted homeostasis during development may lead improved targeted intervention strategies.

Язык: Английский

Процитировано

155

Recipient factors in faecal microbiota transplantation: one stool does not fit all DOI
Camille Danne, Nathalie Rolhion, Harry Sokol

и другие.

Nature Reviews Gastroenterology & Hepatology, Год журнала: 2021, Номер 18(7), С. 503 - 513

Опубликована: Апрель 27, 2021

Язык: Английский

Процитировано

110

Safety and efficacy of fecal microbiota transplantation for treatment of systemic lupus erythematosus: An EXPLORER trial DOI
Cancan Huang, Ping Yi,

Zhu Ming

и другие.

Journal of Autoimmunity, Год журнала: 2022, Номер 130, С. 102844 - 102844

Опубликована: Июнь 1, 2022

Язык: Английский

Процитировано

90

Fecal Microbiota Transplantation as New Therapeutic Avenue for Human Diseases DOI Open Access
Manuele Biazzo, Gabriele Deidda

Journal of Clinical Medicine, Год журнала: 2022, Номер 11(14), С. 4119 - 4119

Опубликована: Июль 15, 2022

The human body is home to a variety of micro-organisms. Most these microbial communities reside in the gut and are referred as microbiota. Over last decades, compelling evidence showed that number pathologies associated with microbiota dysbiosis, thereby suggesting reinstatement physiological microflora balance composition might ameliorate clinical symptoms. Among possible microbiota-targeted interventions, pre/pro-biotics supplementations were shown provide effective results, but main limitation remains limited species available probiotics. Differently, fecal transplantation involves solution matter from donor into intestinal tract recipient order directly change recipient’s aiming confer health benefit. Firstly used 4th century traditional Chinese medicine, nowadays, it has been exploited so far treat recurrent Clostridioides difficile infections, accumulating data coming trials clearly indicate may also carry therapeutic potential for other conditions ranging gastrointestinal liver diseases, cancer inflammatory, infectious, autoimmune diseases brain disorders, obesity, metabolic syndrome. In this review, we will summarize commonly preparation delivery methods, comprehensively review obtained different discuss variability results pivotal importance selection. final aim stimulate discussion open new perspectives among experts use not only infection one first strategies be conditions.

Язык: Английский

Процитировано

80

Promises of microbiome-based therapies DOI Creative Commons
Jasmohan S. Bajaj, Siew C. Ng, Bernd Schnabl

и другие.

Journal of Hepatology, Год журнала: 2022, Номер 76(6), С. 1379 - 1391

Опубликована: Май 16, 2022

Язык: Английский

Процитировано

73

Utilization of the microbiome in personalized medicine DOI
Karina Ratiner, Dragos Ciocan, Suhaib K. Abdeen

и другие.

Nature Reviews Microbiology, Год журнала: 2023, Номер 22(5), С. 291 - 308

Опубликована: Дек. 18, 2023

Язык: Английский

Процитировано

50

Fecal microbiota transplantation: current challenges and future landscapes DOI
Abbas Yadegar, Haggai Bar‐Yoseph, Tanya Monaghan

и другие.

Clinical Microbiology Reviews, Год журнала: 2024, Номер 37(2)

Опубликована: Май 8, 2024

SUMMARYGiven the importance of gut microbial homeostasis in maintaining health, there has been considerable interest developing innovative therapeutic strategies for restoring microbiota. One such approach, fecal microbiota transplantation (FMT), is main "whole microbiome replacement" strategy and integrated into clinical practice guidelines treating recurrent

Язык: Английский

Процитировано

45

Gut-liver axis: Pathophysiological concepts and medical perspective in chronic liver diseases DOI Creative Commons
Susana Rodrigues, Van der Merwe, Aleksander Krag

и другие.

Seminars in Immunology, Год журнала: 2024, Номер 71, С. 101859 - 101859

Опубликована: Янв. 21, 2024

Язык: Английский

Процитировано

19